Check out the amazing line up of speakers!! Please submit and share 🌟 🌈
@jankabatek.com @drbrendannolan1.bsky.social
Posts by Dr Brendan Nolan
Our paper on temporal trends in initiation on gender affirming hormone therapy initiation in Australia is now out in Internal Medicine Journal
@drbrendannolan1.bsky.social
onlinelibrary.wiley.com/doi/10.1111/...
New Opinion article just published 🤓 : Approach to prolactin monitoring and hyperprolactinaemia in transgender and gender-diverse individuals undergoing gender affirming hormone therapy www.frontiersin.org/journals/end... #transgender #transhealth @adacheung.bsky.social @maccatino.bsky.social
Fact or fiction? 🤔 "Being trans is just a fad and social contagion." "There's no evidence, so gender affirming care should be banned." @drbrendannolan1.bsky.social and I answer some of this #misinformation about #transhealth in our latest article 🏳️⚧️ 👉 onlinelibrary.wiley.com/doi/10.1111/...
New longitudinal cohort study of over 3,500 #trans patients finds improvement in depressive symptoms with gender-affirming hormone treatment.
jamanetwork.com/journals/jam...
Key findings:
✅ 46% of individuals achieved serum estradiol within the target range of Australian guidelines.
✅ Median serum estradiol was 396 pmol/L on 1.5 mg (2 pumps) daily.
EstroGel represents a safe alternative first-line option for gender-affirming hormone therapy.
Our recent study explored EstroGel (estradiol 0.06% gel) use in trans and gender-diverse adults 🏳️⚧️ @adacheung.bsky.social
doi.org/10.1111/cen....
Using 22 years of data from Australia’s longest running household survey, we’ve found the mental health of trans, nonbinary, and gender diverse people is worse than cisgender Australians and this gap has been growing - particularly for young people.
theconversation.com/we-tracked-t...
We suggest that treating clinicians should provide this information by using the corresponding gender marker on laboratory requests or provide relevant history to ensure the appropriate laboratory reference ranges are reported.
Once individuals have commenced GAHT, in general, the reference range of the affirmed gender should be reported for laboratory tests with sex-specific reference intervals (including haemoglobin/haematocrit and creatinine).
With increasing numbers of trans people seeking gender affirming hormone therapy (GAHT), it is important that clinicians, pathologists, and laboratory scientists use appropriate reference ranges.